Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets - Wikidata - wikimedia - TriplyDB

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets

http://www.wikidata.org/entity/Q33896539

about

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets

http://www.wikidata.org/entity/Q33896539

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets

@ast

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets

@en

type

label

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets

@ast

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets

@en

prefLabel

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets

@ast

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets

@en

P1433

Q33896539-37D5C7DC-984D-4838-9BA5-E1CE6D1A32D5

P1476

Q33896539-1882E4DE-BECC-447E-BDBF-C195E89AD858

P2093

Q33896539-15352F69-DA22-43FA-B4F5-86757E74C68F

Q33896539-16438E46-E383-4A7C-B72F-50C797357AB5

Q33896539-407C338F-DAAC-48F3-9666-3454D591839B

Q33896539-F6D7D479-7FA7-4FBF-AC19-86AEE1B96A88

P2860

Q33896539-13425A11-2B3D-4C21-9463-E6262A267F21

Q33896539-1FD3935C-9623-44D2-8B2E-60A0FF69CC24

Q33896539-25B5027E-347A-4EE0-B1FD-BF51C88C955D

Q33896539-2B20801C-A165-49C5-8385-392328F5995F

Q33896539-31F4E1CA-D58C-4D7D-98EE-DC4F6B7AD4B7

Q33896539-33E1C1CD-19E2-4A76-A1CB-35B5149F3305

Q33896539-3AF9D86F-B98B-442A-A5D7-51A9E281DA60

Q33896539-3E4D71C4-24FB-4F76-B63C-A09516C40448

Q33896539-4C41E243-7B3D-44D3-894D-ADFC331985E0

Q33896539-61934921-F4C4-45E3-A27C-480DCF6934E8

P304

Q33896539-25CCB1DF-D00D-4F90-AC89-6D2FCB16262C

P31

Q33896539-BD6862E9-4FA9-4F3B-9D85-5EC420C840C8

P356

Q33896539-F57C974C-A430-409B-8FAB-2CB48B1E7519

P433

Q33896539-E297C483-E344-43B9-BD9C-B359C4CDD8BF

P478

Q33896539-E7BFE1F7-93B3-467A-BBBE-05652EA8696E

P577

Q33896539-97931F79-ED58-40B7-867A-FF108830D291

P698

Q33896539-4CBBFF68-B49C-4CFE-B415-6323292D597D

P932

Q33896539-7E0C62EE-1E97-414D-9F99-5EC40D884806

P356

J.JSPS.2016.10.005

P1433

Saudi Pharmaceutical Journal

P1476

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets

@en

P2093

Ayman Elnoby

http://www.w3.org/2001/XMLSchema#string

Hanan M El-Gowelli

http://www.w3.org/2001/XMLSchema#string

Nazik Elgindy

http://www.w3.org/2001/XMLSchema#string

Wael Samy

http://www.w3.org/2001/XMLSchema#string

P2860

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

The effect of drug concentration and curing time on processing and properties of calcium alginate beads containing metronidazole by response surface methodology.

In vitro models of the intestinal barrier. The report and recommendations of ECVAM Workshop 46. European Centre for the Validation of Alternative methods.

Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.

The influence of polymer content on early gel-layer formation in HPMC matrices: The use of CLSM visualisation to identify the percolation threshold.

Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression.

Everted gut sac model as a tool in pharmaceutical research: limitations and applications.

In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.

Preparation and characterization of standardized pomegranate extract-phospholipid complex as an effective drug delivery tool.

Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.

P304

676-687

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JSPS.2016.10.005

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28725139

http://www.w3.org/2001/XMLSchema#string

P932

5506642

http://www.w3.org/2001/XMLSchema#string